Artivion's Q2 2026 Earnings Call: Guidance Caution and Supply Chain Timelines Don't Match

<<>>

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $125.8M for Q2 2026, up 9% YOY
• Gross Margin: Gross margin was 64%, a decrease from 64.7% in Q2 2025
• Operating Margin: Adjusted EBITDA margin was 21%, an approximately 90 basis point decrease YOY

Guidance:

• Revenue for full year 2026 expected to be $480-$496M (constant currency), representing 7%-11% growth.
• Adjusted EBITDA for full year 2026 expected to be $92-$99M.
• Full U.S. commercial launch of the Nexus system anticipated in January 2027.
• 2027 adjusted EBITDA expected to be non-neutral as U.S. Nexus revenue ramps, with R&D and clinical spending targeted at 7%-8% of sales.

Business Commentary:

Revenue and Product Growth:

• Artivian reported total revenue of $125.8 million for Q2 2026, up 9% compared to Q2 2025. Adjusted EBITDA increased approximately 7% year-over-year.
• The growth was driven by an 18% increase in Onyx revenues and a 12% increase in StentCraft revenues, attributed to strong market share gains and favorable clinical data.

AMDS and Regulatory Milestones:

• The company received U.S. FDA approval for the PMA for its AMDS hybrid prosthesis in late June 2026.
• This approval is expected to accelerate new account conversion and remove barriers associated with the initial investment, facilitating further growth in AMDS set sales.

Acquisition and Market Expansion:

• Artivian completed the acquisition of Endospan and its Nexus Aortic Arch StentGraph system during Q2 2026, ahead of schedule.
• This acquisition completes their market-leading aortic arch portfolio, positioning them as a global leader in this segment and unlocking a $100 million market opportunity.

International Growth and Challenges:

• International revenues grew by 10%, with notable increases in Asia Pacific and Latin America, while EMEA saw a return to growth after a decline in Q1.
• The improvement was supported by a return to growth across international markets, despite supply chain challenges that were expected to persist through the year.

Tissue Processing and Pipeline Development:

• Tissue processing revenues grew 1% year-over-year, slightly ahead of expectations, recovering from the 2024 cyber incident.
• The company continues to make progress on its Artisan clinical trial for the SIVO LSA product, with 30 patients enrolled, aiming to unlock an incremental $80 million U.S. market opportunity upon FDA approval.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed being 'very pleased' with Q2 performance, citing 'meaningful progress' including AMDS PMA approval and the Endospan acquisition ahead of schedule. They noted 'strong early commercial momentum' and 'super excited' about the long-term growth pipeline, describing the company as 'rare' in receiving multiple PMAs in a year.

Q&A:

• Question from Zachary (Canaccord Genuity): Q2 revenue beat by a nice bit. Why not raise the guidance? What does it imply for the back half of the year, more specifically on product line, especially with some of the drivers you have, AMDS getting approval?
  Response: The beat was driven by prior guidance assumptions (AMDS PMA, Endospan acquisition) and a timing shift in preservation services revenue. Management felt it was prudent to maintain guidance given challenged service business until further into the year.

• Question from Zachary (Canaccord Genuity): For the number of accounts currently with AMDS on the shelf and those either in VAC approval or purchasing of inventory... Just any comment on that.
  Response: Management did not provide specific account-level details but noted improved AMDS set sales and new account openings in Q2 compared to Q1, and that the PMA approval allows more aggressive marketing without IRB hurdles.

• Question from Seamus (Oppenheimer): Just to start, Pat, can you talk a little bit more about kind of AMDS?... why was it a barrier before and why is it not so much now?
  Response: The $100k set price was a barrier due to administrative friction (IRB, VAC approval delays). Management spent Q2 understanding these barriers and expects accelerating adoption in the second half post-PMA, though the price itself did not change.

• Question from Seamus (Oppenheimer): ...we'll say six months or so from now, kind of January Nexus is launched. How are you guys kind of balancing kind of the sales force of selling?
  Response: The U.S. commercial team (~60 people) focuses on aortic cardiac surgeons for Onyx/AMDS. A small dedicated vascular team will cover the ~150 target Nexus accounts, working synergistically with the cardiac team.

• Question from Joseph (Needham and Company): Question on maybe international strip stent growth. You know, maybe how did that trend in the quarter?
  Response: International growth improved to 10% in Q2 from a decline in Q1, with progress on supply chain issues. The Middle East conflict contributed some revenue but is not relied upon for guidance.

• Question from Joseph (Needham and Company): ...any updated thoughts on the manufacturing site there in Israel... And then just to clarify, reps specifically for AMDS following approval?
  Response: Management is committed to the Endospan manufacturing facility in Israel for the near term, with contingency plans in development. No additional AMDS reps are planned for the second half; coverage is sufficient via current channels.

• Question from Frank Kekkonen (Lake Street Capital Markets): I wanted to talk about free cash flow a little bit more... can you just remind us if there are initial thoughts on 2027?
  Response: 2026 free cash flow is negative due to acquisition-related accounting and CapEx. 2027 is expected to be meaningfully positive as these one-time expenses do not repeat and EBITDA grows.

Contradiction Point 1

Guidance Adjustment Following Q2 Revenue Beat

It involves a contradiction in financial forecasting regarding whether to raise guidance after a strong quarter, impacting investor expectations for company performance.

Bill Plovenich (Canaccord Genuity) - Bill Plovenich (Canaccord Genuity)

2026Q2: Given the challenging start to the year for Tissue Services, it was prudent to maintain the existing guidance and not raise it at this time. - [Pat Mackin](CEO) and [Lance Berry](COO and CFO)

Given the Q2 revenue beat, why wasn't guidance raised, and what does this indicate for the back half of the year, particularly considering drivers like AMDS approval? - Zachary (Canaccord Genuity)

2026Q2: The strong Q2 performance... provides more confidence. However, given the challenging Q1, management chose to maintain a conservative stance and therefore did not raise guidance. - [Lance Berry](COO)

Contradiction Point 2

International Supply Chain Recovery Timeline

It involves differing expectations on the timeline for resolving international supply chain issues, affecting strategic planning and capital expenditure outlook.

Mike Mattson (Needham and Company) - Mike Mattson (Needham and Company)

2026Q2: Supply challenges were expected to persist through 2026, but progress was made in Q2, with confidence for a full recovery by early 2027. - [Pat Mackin](CEO) and [Lance Berry](COO and CFO)

How did international StentGraph growth trend, and have supply chain/Middle East conflict issues, including the EndoSpan manufacturing site in Israel, eased? - Joseph (Needham & Company)

2026Q2: Supply chain progress was better than expected in Q2, and the company is more confident in being back to full strength by early 2027, though 2026 guidance is unchanged. - [Lance Berry](COO)

Contradiction Point 3

AMDS PMA Approval Impact and Adoption Timeline

It involves differing views on how the PMA approval affects AMDS adoption and sales, influencing growth expectations.

What questions did Keith Hinton from Freedom Capital Markets raise during the earnings call? - Keith Hinton (Freedom Capital Markets)

2026Q2: No immediate avalanche effect. The PMA removes a point of friction... with expectations for accelerated adoption in the back half. - [Pat Mackin](CEO)

Will the AMDS PMA approval result in an immediate impact or enable a step-change increase by reducing friction? - John McAulay (Stifel)

2026Q1: PMA approval... is anticipated to help ease hospital IRB processes... The guidance reflects current trends and includes efforts to mitigate these issues. - [Lance Berry](CFO)

Contradiction Point 4

NEXUS Manufacturing Readiness for U.S. Launch

It involves conflicting statements on the status of manufacturing readiness for the U.S. launch of NEXUS, affecting expectations for product availability.

Mike Mattson (Needham and Company) - Mike Mattson (Needham and Company)

2026Q2: The EndoSpan facility in Israel is a PMA-approved site with no supply chain issues to date. - [Lance Berry](CFO)

How did international StentGraph growth trend, have supply chain/Middle East conflict issues eased, and are there any updated thoughts on the EndoSpan manufacturing site in Israel? - Bill Plovanic (Canaccord Genuity)

2026Q1: NEXUS is already manufactured in Europe, but no inventory has been built for a U.S. launch. - [Lance Berry](CFO)

Contradiction Point 5

Tissue Processing (Tissue Services) Performance Outlook

It involves a contradiction in describing the trend and stability of the Tissue Processing business, affecting overall company performance assessment.

Bill Plovenich (Canaccord Genuity) - Bill Plovenich (Canaccord Genuity)

2026Q2: Given the challenging start to the year for Tissue Services, it was prudent to maintain the existing guidance... - [Lance Berry](CFO)

Why wasn't guidance raised despite the Q2 revenue beat, and what does this imply for the back half of the year, particularly with drivers like AMDS approval? - Jeffrey Cohen (Ladenburg Thalmann)

2026Q1: Tissue processing revenue was strong in Q1 ($24M+ per quarter) and is considered to be within normal quarterly variability. - [Lance Berry](CFO)

<<>>